You are here

  • Home
  • Archive
  • Volume 95, Issue 9
  • Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a randomised, subject-blind, investigator-blind, placebo-controlled, phase 2a trial and open-label extension study

Citation Tools

Article menu

Download PDFPDF

Neuromuscular
Original research
Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a randomised, subject-blind, investigator-blind, placebo-controlled, phase 2a trial and open-label extension study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Querol L, De Sèze J, Dysgaard T CIDP01 Study Investigators, et al
Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a randomised, subject-blind, investigator-blind, placebo-controlled, phase 2a trial and open-label extension study
Journal of Neurology, Neurosurgery & Psychiatry 2024;95:845-854.